Every 424B that Viking Therapeutics, Inc (VKTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VKTX filings page.
Viking Therapeutics, Inc. is offering $225 million of 2.00% convertible senior notes due October 15, 2032, with an underwriters’ option to purchase up to an additional $33.75 million solely to cover over-allotments. Estimated net proceeds are $218.0 million, or $250.8 million if the option is exercised in full. Viking intends to use the proceeds for VK2735 clinical development, advancement and commercialization; VK3019 clinical development and advancement; and other research and development, working capital and general corporate purposes.
Separately, Viking is offering 7,857,143 common shares, plus an option for up to 1,178,571 shares; completion of either offering is not contingent on the other. The notes pay 2.00% annual interest semiannually beginning April 15, 2027. Their initial conversion rate is 19.7044 shares per $1,000 principal amount, equivalent to an approximately $50.75 conversion price; conversion is available only under specified conditions. In the VK2735 maintenance study, every-other-week dosing maintained up to 97% of mean weight loss from the weekly induction phase, versus 61% for placebo; monthly dosing maintained up to 90%, versus 61%.
Viking Therapeutics, Inc. (VKTX) is offering 7,857,143 common shares at $35.00 per share, with estimated net proceeds of approximately $258.2 million. Underwriters have a 30-day option to buy up to 1,178,571 additional shares; estimated net proceeds would be approximately $297.0 million if exercised in full. Viking intends to use proceeds for VK2735 and VK3019 development, research and development, working capital and general corporate purposes.
Separately, Viking is offering $225 million of 2.00% convertible senior notes due 2032, with an option for up to $33.75 million more. The note offering is not contingent on the stock offering; if completed, its estimated net proceeds are approximately $218.0 million.
In VK2735 maintenance-study results, after 21 weeks of weekly treatment and 12 weeks of maintenance dosing, every-other-week groups maintained up to 97% of mean weight loss achieved during induction, versus 61% for placebo; monthly groups maintained up to 90%, also versus 61%. During induction, weight loss ranged approximately 16% to 19%, compared with approximately 0% for placebo.
Viking Therapeutics, Inc. is offering convertible senior notes due October 15, 2032, alongside a separate common-stock offering; neither offering is contingent on the other. Noteholders may convert in specified circumstances, and Viking may elect to settle conversions in cash, common shares or a combination. Viking intends to use the note proceeds, together with proceeds from the stock offering if completed, for its VK2735 and VK3019 programs, other research and development, working capital and general corporate purposes.
The notes are senior unsecured obligations and structurally subordinated to subsidiary liabilities. As of June 30, 2026, Viking’s subsidiaries had approximately $79.8 million of indebtedness and other liabilities; Viking, excluding its subsidiaries, had no indebtedness for borrowed money.
In VK2735’s maintenance study, weight loss after the 21-week induction ranged approximately 16% to 19%, compared with approximately 0% for placebo. During the 12-week maintenance phase, every-other-week dosing maintained up to 97% of mean induction weight loss and monthly dosing up to 90%, compared with 61% for placebo in each comparison. Gastrointestinal-related adverse-event rates during maintenance were comparable to placebo.
Viking Therapeutics, Inc. is conducting a primary common-stock offering, with proceeds to the company after underwriting discounts and estimated offering expenses. The stock offering and a separate concurrent convertible-note offering are not contingent on each other. Viking intends to use stock-offering proceeds together with proceeds from the note offering, if completed, for continued work on VK2735 and VK3019, research and development, working capital, and general corporate purposes.